# The Quarterly Publication of the British Leprosy Relief Association 

## LEPROSY REVIEW

## VOLUME XXXIX NO. 1 JANUARY 1968

PRINCIPAL CONTENTS

Editorial
B663 in Lepromatous Leprosy
Neurological Lesions in Leprosy
Pro-oxidant Diets in Mycobacterial Infections
Apamarga in the Treatment of Lepromatous Leprosy
Acute Epididymo-Orchitis in Lepromatous Leprosy
Lepromatous Leprosy Treated with N' Acetyl Sulphamethoxypyridazine
Preventive Rehabilitation in Leprosy
A Survey of an Experimental Rehabilitation Unit
Report
Letters to the Editor
Abstracts
Book Review
Editorial Office
6 HILLCREST AVENUE, PINNER, MIDDLESEX, ENGLAND

Single Issue 10s. 6d., plus postage Annual subscription $£ 2$ sterling (U.S. \$6)

# LEPROSY REVIEW <br> VOLUME XXXIX NO. ! JANUARY 1968 

## Contents

Page
Editorial ..... 2
B663 in Lepromatous Leprosy. Effect in Erythema Nodosum Leprosum, by Robert C. Hastings and John R. Trautman ..... 3
Neurological Lesions in Leprosy, by C. L. Crawford ..... 9
The Effect of Pro-oxidant Diets on some Experimental Mycobacterial Infections, わy Meny Bergel.. ..... 15
Apamarga (Achyranthes Aspera) in the Treatment of Lepromatous Leprosy, by D. Оjha and G. Singh ..... 23
Acute Epididymo-Orchitis in Lepromatous Leprosy, by C. T. Tilak ..... 31
Lepromatous Leprosy Treated with N' Acetyl Sulphamethoxypyridazine, by J. C. Hathaway ..... 37
Preventive Rehabilitation in Leprosy (in three parts), Parts 1 and 2, by S. Karat ..... 39
A Survey of the Results of Residence in an Experimental Rehabilitation Unit for Leprosy Patients, by E. P. Fritschi, A. J. Selvapandian, S. Koshy and S. R. Radhakrishnan ..... 45
Report ..... 51
Letters ..... 53
Abstracts ..... 55
Book Review ..... 58

The Association does not accept any responsibility for views expressed by writers. All communications re Leprosy Review and all subscriptions should be sent to the Editor.

Editor: Dr. James Ross Innes, m.d. (edin.), d.t.m. (Liv.)
Editorial Office: 6 Hillcrest Avenue, Pinner, Middlesex, England Tel.: 01-866 2237


 ă 形 $\$$


> 'It is a testimonial to Dr. James A. Doull, the author of the first edition of the Bulletin on Leprosy, dated March 15,1954 , that that bulletin has sustained a high demand for copies in the intervening ll years since its publication. After a distinguished career, at Brompton Hospital in London, John Hopkins University, Western Reserve University, and with the U.S. Public Health Service, in 1948 Dr. Doull assumed the position of Medical Director of the Leonard Wood Memorial (American Leprosy Foundation). Under his guidance the first scientific method for evaluating the chemotherapy of leprosy in man wes evolved, to which reference is made in this revision. The authors of the revision of Dr. Doull's original article, Drs. Guinto and Binford, were long time associates of Dr. Doull's, and it is believed that this revision will be as authoritative, and in as much demand as was the original bulletin. This second bulletin on Leprosy, therefore, may serve as an additional fitting tribute to the memory of Dr. Doull who died on April $6,1963$.
ă กั $1 / 4 \hat{n} 7($ \#
 leprosy workers throughout the world $\varrho^{\circ} \dot{A} * \hat{n}$
 \& \# \#n "




 1/4 (豊




As from 27 November, 1967, the Headquarters of LEPRA (The British Leprosy Relief Association) will be transferred from the present offices at 8 Portman Strcet, London, W.l, to 50 Fitzroy Street, London, W.I.
The new Headquarters, in which the office of the Medical Secretary of LEPRA will be situated, are conveniently near the main railway terminals for trains going north from London, and are also within a short distance of Great Portland Street and Warren Street Underground stations.

The Editorial Office for Leprosy Review will continue to be located for the time being at 6 Hillcrest Avenue, Pinner, Middlesex.

We send our greetings to the General Secretary of LEPRA and his Staff and our best wishes for the campaign against leprosy waged by the Association.

## : EMDE MDE \& $\&$ GE\&?

## LONDON - 16th-21st SEPTEMBER

## 












[^0]
# B663 in Lepromatous Leprosy. Effect in Erythema Nodosum Leprosum ${ }^{\star}$ 

ROBERT C. HASTINGS, m.d. Deputy Chief, Clinical Branch, USPHS Hospital, Carville, La., U.S.A.<br>JOHN R. TRAUTMAN, м.d.<br>Deputy Medical Officer in Charge, USPHS Hospital, San Francisco, California, U.S.A. (Formerly Chief, Clinical Branch, USPHS Hospital, Carville, La., U.S.A.)

B663 is a riminophenazine derivative. The antimycobacterial activity of this class of drugs was reported in $1948^{1}$. In 1952 a derivative of these compounds, B283, was used in the treatment of leprosy ${ }^{2}$. More recently B663 has been used in the treatment of murine leprosy ${ }^{34}$, mouse footpad infections with Mycobacterium leprae ${ }^{5}$, and in several clinical trials in human leprosy ${ }^{678}{ }^{7} 910111213141516$.

Conclusions reached concerning the riminophenazines and B663 in particular include the following: (1) the drug is effective against a number of mycobacteria ${ }^{117}$, including Mycobacterium lepraemurium ${ }^{34}$ and Mycobacterium leprae ${ }^{5678910111213141516}$, (2) the drug is apparently free of serious toxic side effects in both animals ${ }^{318}$ and in humans ${ }^{111^{1316}}$. In man and animals these compounds produce reddish skin pigmentation ${ }^{236111316}$. The effect of B663 on erythema nodosum lepıosum(ENL) reactions in lepromatous leprosy has recently been a subject of controversy. Several studies have indicated that B 663 is beneficial in $\mathrm{ENL}^{9}{ }^{1213}$. On the other hand, Pettitt ${ }^{15}$ has recently claimed that B663 has no effect on ENL. The present communication deals with the effect of B663 on patients with ENL reactions at the U.S. Public Health Service Hospital, Carville, La. methods
Six patients with active lepromatous leprosy associated with established erythema nodosum leprosum reactions, all requiring regular corticosteroid therapy, were selected for a trial of treatment with B663. Another group of 6 patients was selected by matching with the

B663 group as nearly as possible for the factors of age, sex, race, classification of leprosy, bacteriological status, duration of leprosy, current anti-leprosy treatment, duration of ENL, and severity of ENL as measured by current steroid requirements. The second group was given regular anit-leprosy treatment with intramuscular Solapsone B.P. (Sulphetrone). The clinical data are summarized in Table 1.

The dosage of B663 employed was usually 100 mg .3 times daily by mouth, although this varied somewhat, particularly early in the study. The dosage of Solapsone was usually 0.1 ml . of the $50 \%$ aqueous solution intramuscularly per week initially, and with the dose being raised at 2 -week intervals by 0.1 to 0.2 ml . per week, when feasible, until a maximum dosage of 2.0 ml . per week was achieved. The average dosages of B663 and Solphetrone for each calendar month of the study are given in Table 2.

Each patient was seen from once daily to once weekly as long as ENL reactions were present, and corticosteroids were prescribed by one of the authors (R.C.H.) in the least dosage which would prevent (1) debilitating fever, (2) ulceration of ENL, (3) reactive neuritis producing anaesthesia of the palms, soles or cornea, and (4) reactive neuritis producing any motor weakness. The corticosteroid preparations used were oral prednisone U.S.P., injectable prednisolone sodium phosphate U.S.P. (Hydeltra-

[^1]CLINICAL DATA AT THE BEGINNING OF TREATMENT


| $* 4$ | $=$ numerous $=$ hundreds of acid-fast bacilli/oil immersion field |
| ---: | :--- |
| 3 | $=$ moderate $=10$ to $100 \mathrm{AFB} /$ o.i.f. |
| 2 | $=$ few $=$ fewer than $10 \mathrm{AFB} /$ o.i.f. |
| 1 | $=$ rare $=$ fewer than $10 \mathrm{AFB} /$ entire smear |
| 0 | $=$ none found $=$ no AFB in 50 oil immersion fields |

$\mathrm{Su}=$ Sulfadimethoxine (Madribon(R)—Roche)
So $=$ Solapsone B.P. (Sulphetrone)
$\mathrm{Sm}=$ Streptomycin
DDS $=$ diaminodiphenyl sulfone (Dapsone)
** None of anti-leprosy treatment regularly taken. Amounts shown are average.

TABLE 2
MEAN DOSAGES OF SOLAPSONE IN ML. OF 50\% AQUEOUS SOLUTION PER WEEK AND B663 IN MG. PER DAY

| SOLAPSONE GROUP Patient | MONTH* |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 0 | $+1$ | +2 | $+3$ | +4 | +5 | +6 | +7 | +8 | $+9$ |
| S-1 | 0.15 | 0.25 | 0.5 | c. 9 | 1.3 | 1.5 | 0.9 | 0.8 | 1.0 | 1.0 |
| S-2 | 0.05 | 0.1 | 0.3 | 0.5 | 1.1 | 1.6 | 2.0 | 2.0 | 2.0 | 2.0 |
| S-3 | 0.05 | 0.2 | 0.35 | 0.8 | 1.1 | 1.45 | 1.6 | 1.6 | 1.9 | 2.0 |
| S-4 | 0.05 | 0.1 | 0.1 | 0.03 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 |
| S-5 | 0.07 | 0.5 | 0.4 | 0.6 | 0.6 | 0.8 | 0.8 | 0.4 | 0.4 | 0.25 |
| S-6 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.35 | 0.4 | 0.6 |
| Miean | 0.08 | 0.23 | 0.31 | 0.51 | 0.73 | 0.94 | 0.95 | 0.89 | 0.98 | 1.01 |
| B663 GROUP Patient |  |  |  |  |  |  |  |  |  |  |
| B-I | 150 | 167 | 300 | 300 | 100 | 200 | 200 | - | - | - |
| B-2 | 30 | 300 | 200 | 250 | 300 | 300 | 300 | 300 | 300 | 300 |
| B-3 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 |
| B-4 | 100 | 200 | 267 | 300 | 300 | 300 | 300 | 300 | 300 | 300 |
| B-5 | 13 | 250 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 |
| B-6 | 100 | 200 | 267 | 150 | 35 | 100 | 100 | 100 | 120 | 200 |
| Mean | 115 | 236 | 272 | 267 | 223 | 250 | 250 | 260 | 264 | 280 |

*Note: The 0 month indicates the calendar month in which the medication was begun; +1 indicates the first full calendar month of treatment, etc.

 2\$*

 2\$*









| SOLAPSONE GROUP Patient | -3 | -2 | -1 |  | $+1$ | +2 | $\begin{gathered} \text { MONTH* } \\ +3 \end{gathered}$ | +4 | +5 | +6 | +7 | +8 | $+9$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| S-I | 19.9 | 44.0 | 60.5 | 43.0 | 49.5 | 40.0 | 37.5 | 36.0 | 56.7 | 79.3 | 56.9 | 20.5 | 30.5 |
| S-2 | 0 | 0 | 0 | 6.5 | 17.3 | 9.0 | 7.3 | 9.8 | 11.8 | 12.4 | 9.5 | 9.9 | 11.2 |
| S-3 | 0 | 3.8 | 8.8 | 41.2 | 43.9 | 47.6 | 57.8 | 58.7 | 68.7 | 76.0 | 64.6 | 70.0 | 68.6 |
| S-4 | 3.9 | 20.1 | 7.0 | 10.3 | 18.5 | 26.9 | 29.2 | 27.2 | 28.0 | 49.2 | 41.4 | 39.0 | 28.6 |
| S-5 | 1.6 | 4.7 | 8.7 | 9.9 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 11.8 | 16.2 | 15.0 | 20.0 |
| S-6 | 16.2 | 15.0 | 29.1 | 29.5 | 31.3 | 39.7 | 43.5 | 40.3 | 40.1 | 43.3 | 39.5 | 40.4 | 32.7 |
| Mean | 6.9 | 14.6 | 19.0 | 23.4 | 28.4 | 28.9 | 30.9 | 30.3 | 35.9 | 45.3 | 38.0 | 32.5 | 31.9 |
| Mean for 3 mo. interval |  | 13.5 |  |  |  | 29.39 |  |  | 37.18 |  |  | 34.13 |  |
| B663 GROUP Patient |  |  |  |  |  |  |  |  |  |  |  |  |  |
| B-I | 56.7 | 62.7 | 76.5 |  |  |  |  |  |  |  | - | - | - |
| B-2 | 20.2 | 15.1 | 14.0 | 14.1 | 20.4 | 26.8 | 17.7 | 7.9 | 5.0 | 10.0 | 9.3 | 7.8 | 2.8 |
| B-3 | 11.2 | 25.8 | 15.8 | 22.4 | 21.4 | 14.1 | 21.6 | 22.4 | 17.9 | 19.6 | 14.6 | 14.7 | 15.9 |
| B-4 | 0 | 4.4 | 8.7 | 21.8 | 28.0 | 29.7 | 2.2 | 0 | 0 | 0 | 0 | 0 | 0 |
| B-5 | 18.6 | 18.8 | 11.0 | 10.5 | 11.5 | 13.5 | 14.8 | 17.0 | 20.0 | 20.8 | 21.0 | 21.4 | 20.4 |
| B-6 | 3.7 | 6.5 | 28.0 | 44.0 | 16.8 | 1.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mean | 18.4 | 22.2 | 25.6 | 29.0 | 23.5 | 17.5 | 11.8 | 8.8 | 7.2 | 8.4 |  |  |  |
| Mean for 3 mo. interval |  | 22.09 |  |  |  | 17.58 |  |  | 8.13 |  |  |  |  |

* The calendar month in relation to the month in which treatment was started; for example, 0 month refers to month in which treatment was started, HI indicates first full calendar month after treatment was started, etc



 " 吸(GUTN2\$*




 \#3 \% Gî̃'/




RESULTS



X\& -\%\#\#3(Gก̃̃* ' \% 2\#*


 \#2\% * Nֹ \&



 \# 3 \% กั̃ 3 /N \$" ก̃̃\#2 !ế !' 2(ÀG




 e" (J З\# \$ ก̃̃ư) 7 ก̃̃\$"E


و\$ñ̃ \& กñ\#'"\$*

 ü ĝ) !\%*






X\& ก̃̃\# \%!*


 q2 23 \%
\％＿4 ก̂̃F由 R
 $\& 1 F \hat{T}$ L ก̣̃is Ěs

## DISCUSSION

q กั\＆\＆
 $0+7 \% \#$ 雪 nü！＇\＆




\％＋＋（（G


 \＆$+\%$＂＂$\%$ सी


 \＃U＂L＋ビビ
 7D + \％

 $\%$ \％\＃\＄గ！（ $+7 \%$ \＃







## SUMMARY




 n！\＆
 ！$\sigma$ ëñ \＆\＄莒＂




## ACKNOWLEDGEMENT





## REFERENCES

1．Barry，vincent C．，belton，J．G．，Conalty，m．L． and Twomsy，B．Anti－tubercular activity of oxidation products of substituted o－phenylene diamines．Nature，162，622－623（Oct．16） 1948.
2．allday，E．J．and Barnes，J．Treatment of leprosy with B283．J．Med．Sci．，6，421－425， 1952.

3．CHANG，Y．T．Effects of B663，a rimino compound of the phenazine series，in murine leprosy． Antimicrobial Agents and Chemotherapy，ed．by Sylvester，J．C．，Ann Arbor，Mich．，American Society for Microbiology，1962，pp．294－307．
4．CHANG，Y．T．Further studies on B663 in murine leprosy．Absence of resistance of $M$ ．lepraemurium to B 663 and delay in development of resistance to isoniazid．Int．．J．Lepr．，34，1－6， 1966.
5．Sheprard，c．C．and Chang，y．T．Activity of anti－ tuberculosis drugs against Mycobacterium leprae． Studies of experimental infection of mouse foot－ pads．Int．J．Lepr．，32，260－271， 1964.
6．BROWNE，s．G．and HOGERZEIL，L．M．＇B663＇in the treatment of leprosy．Preliminary report of a pilot trial．Lep．Rev．，33，6－10，1962．
7．BROWNE，s．G．and HOGERZEIL，L．M．＇B663＇in the treatment of leprosy．Supplementary report of the pilot trial．Lep．Rev．，33，182－184， 1962.
8．Browne，s．G．and hogerzeil，L．M．Apparent resistance of $M$ ．to＇ B 66 6 3 ＇．Lep．Rev．， 33，185－189， 1962.
9．BROWNE，s．G．＇B663＇－Possible anti－inflammatory action in lepromatous leprosy．Lep．Rev．，36，9－11， 1965.

I（）．BROWNE，s．c．Treatment of leprosy with B663． Appraisal of the pilot trial after three years． Lep．Rev．，36，13－15， 1965.
11．BROWNE，s．G．Red and black pigmentation developing during treatment of lejprosy with ＇B663＇．Lep．Rev．，36，17－20， 1965.
12．BROWNE，s．g．B663（Geigy）．Further observations on its suspected anti－inflammatory action．Lep． Rev．，37，141－145， 1966.
13 थ̛̣̂ WILLIAMS，T．W．，JR．，MOTT，P．D．，WERTLAKE，P．T．， BARBA RUBIO，J．，ADLER，R．HII，L ，G．J．，II， PEREZ SUAREZ，$G$ ．and KNIGHT，V．Leprosy research at the National Institutes of Health， experience with B 663 in the treatment of leprosy． Int．J．Lepr．，33，767－775（Part II），1965．
14．pettit，J．H．S．and Rees，R．J．w．Studies on sulfone resistance in leprosy．2．Treatment with a riminophenazine derivative（ B 663 ）．Int．J．Lepr． 4，391－397， 1966.
15．Pettit，J．h．s．The treatment of erythema nodosum leprosum with B663．A controlled study． Int．．J．Lepr．，35，11－16， 1967.
16. pettit, J. h. s., rees, r. J. W. and ridley, d. S. Chemotherapeutic trials in leprosy. 3. Pilot trial of a riminophenazine derivative, B663, in the treatment of lepromatous leprosy. Int. J. Lepr., 35, 25-33, 1967.
17. barry, v. c. and conalty, m. l. The antimycobacterial activity of B663. Lep. Rev., 36, 3-7, 1965.
18. conalty, m. L. and Jackson, R. D. Uptake by reticulo-endothelial cells of the riminophenazine B663 (2-P-chloroanilino, 5-P-chlorophenyl-3: 5-dihydro-3-isopropyl iminophenazine). Brit. .J. Exp. Path., 43, 650-654, 1962.
19. bancroft, huldah. Introduction to Bio-statistics, New York, Hoeber-Harper, 1st Ed., 1957, 172-182.
20. jopling, w. h. Treatment of acute phases (reactional states) in lepromatous leprosy. Leprosy in Theory and Practice, Cochrane, R. G. and Davey, T. F., Eds., Williams \& Wilkins Co., Baltimore, 2nd Ed., 1964, 419.
21. cochrane, r. g. Therapy. Leprosy in Theory and Practice, Cochrane, R. G. and Davey, T. F., Eds. Williams \& Wilkins Co., Baltimore, 2nd Ed., 1964, 385.
22. trautman, john r. The management of leprosy and its complications. New Eng. J. Med., 273, 756-758 (Sept. 30) 1965.
23. hastings, r. c. and trautman, J. r. Unpublished data.

## ORIG?G 8:,\&?[0 L:GEEI 2 HIGWI

##  <br> 

q\$ ฤ! 4 \% ก̃̃ \$




 !\$3"C! 4 กñ - " \&













s" \& గ̃ " $\mathrm{S} \%=\varnothing$ \% \&



 \% $\%$ = b3\% (^ \# ก̃̃ 3\$=





 \% \$ñ̃=" ? \$




 "
 ã' = ! $3^{\prime \prime}(3$ =iñ!
 ? \& и
materials and methods
" ((ñ . 1 笛"/ñ̃( ě\%\# ก̃̃? \% d ! \$ \# \#in? ǵ\& \# 3 \%
 XÆ \# ก̃̃? \%
 , 1 ب̂̃

 m \% !" \$ñ "IJก̃̃ \& ก̃̃ \%





 $\$=\hat{T} ? \%$ \%
q\$
 \&" \# గ̃ $\quad$ !





 \$) \% !" $\$$ ก̃̃?



 d !ǨS \#in? \%


 í ！\＆

## RESULTS

 \＄）\％（＂Ș！＇（ஸ̃̃ \＃＂\＄

## Group 1䇶


 \＃ỮO\＄


are some slight dimorphous
$X \&$ ท̃̃ ？（IJ \＆

$0^{\prime}$ \＃त्र \＃



 some slight diゆ口
 ous
š！－）！＂\＄ ？○荆＂





 t

Patient l－A boy of about 16 years was admitted on 7.1 .67 with pain and oedema of both hands，feet and face．There were widespread，moderately well defined， macular lesions over trunk and limbs．Neurological examination was normal．Dexamethasone was started on $7 . l .67$ to reduce the pain and oedema， starting with 12 tablets of 0.5 mg daily and reducing the dose by 0.5 mg a day，so that the course finished on 18．1．67．This gave relief of p ain and oedema，but early in February there was a recurrence of symptoms so that Dexamethasone was recommenced on 10．2．67 and stopped on 17．2．67．This again gave immediate temporary relief，but as soon as the course finished there was another recurrence．A further course of steroids was thought inadvisable and hence Camoquin was started on 13.3 .67 and continued until 1.4 .67 ．The pain and oedema finally subsided early in April．Some weeks later it was observed that there were blisters on one of the fingers，and neurological examination then showed sensory loss，involving both hands and feet，of ＇glove and stocking＇distribution．After 3 months＇


Fig. 6
Effect of the prooxidant diet on the mortality of mice inoculated with BCG Phipps after 14 days on diet.

##  



 $6!$ (9̃a\$ ! $\$$ ñ $+\infty$ ñ E \% กỉ $\$ 6$ ) 0 *
 U ! 4 4 , $\$$




 EÁfin cin



20
30 days
40

Fig. 7
Effect of the prooxidant diet on the mortality of mice inoculated with $M$. fortuitum Penso after 21 days on diet. Ordinates indicate number of mice surving at different period of time after infection (abscissae).
$10 \quad 20 \quad 30 \quad 40$ days 50

Fig. 8
Effect of the prooxidant diet on the mortality of mice inoculated with $M$. fortuitum Penso after 36 days on diet. Ordinates indicate number of mice surviving at different periods of time after infection (abscissae).

## ${ }^{3}$ ต̌ 





 ロ




 1 Úe Õ7 \% \$ \#



 7 \% 6\$ ((.

 6/ గั่

 6ท̂̃\#



Fig. 13
Effect of the prooxidant diet on the mortality of mice inoculated with Klebsiella pneumoniae (Friedländer) after 42 days on diet. Ordinates indicate number of mice surviving at different period of time after infection (abscissae)


Fig. 14
Effect of the prooxidant diet on the mortality of mice inoculated with L.PS ( 200 mcg . in 0.2 ml . intraperitoneally) after 42 days on diet. Ordinates indicate number of mice surviving at different periods of time after inoculation (abscissae).

$$
\begin{aligned}
& 6 \text {------ --- ---- -- -- ---------------- } \\
& \text { Pellets } \\
& \text { *+,' ' \% } 10 \text { oil } \\
& \stackrel{n}{0} \\
& \text { \& - , } 1 \text { 2 }
\end{aligned}
$$

Fig. 15
Effect of the prooxidant diet on the mortality of mice inoculated with LPS ( 400 mcg . in 0.2 ml . intraperitoneally) after 42 days on diet. Ordinates indicate number of mice surviving at different periods of time after inoculation (abscissae).


Fig. 4
G.L.S.C. 201/63-Lymph node in Leprosy. $\mathrm{H} \& \mathrm{E} \times 80$. Illustrates lymph node showing follicular hyperplasia with pale epithelioid cells thickening of capsule with A.F.B. $5 \%$ positive.


Fig. 5
G.L.S.C. 201/63. H \& E $\times 80$.

Skin in leprosy-shows collections of histiocytes at one end.
deferens shows evidence of infiltration, with few chronic inflammatory cells-A.F.B. positive. TestisFibrosis, thickening of Basement membraneA.F.B. positive. Hydrocele fluid-nil particularBone marrow autolysed.
Note: Though the testis and adnexa with other biopsy specimens were sent the pathologists overlooked the histopathological study of the epididymis.
Patient 3-G.L.S.C. No. $105 / 59$. V.N.B. Age 38 years. Indian Christian, educated, Government employee, married, 2 children. History of leprosy 2.5 years. History of lepra reaction 15 years.
Patient first examined by Dr. Cochrane at Vellore during early 1948 - has been under regular treatment since then. His first attack of epididymo-orchitis was during October, 1963, and the present attack in June, 1967 -the duration of attacks being 15 and 12 days respectively. On both occasions the patient was under the author's observation and treatment. He exhibits marked gynaecomastia of the right breast and has been impotent and sterile for the past 8 years. The patient did not consent to testicle biopsy.
Patient 4-G.I.S.C. No. 280/64. S. S. Sahib Age 35 years. Muslim, illiterate, sharescropper, married, 5 children. History of leprosy 15 years. History of lepra reaction 7 years. Semblance of libido present.
Apart from his acute epididymo-orchitis the patient had marked cervical lymphadenopathy and lepromatous infiltration with development of an extensive patch over the right forearm in a skin area previously scalded in early childhood. Both the nipples and surrounding skin area were bilaterally infiltrated.
The patient was willing to have biopsy but refused orchidectomy. The following biopsy specimens were taken: (a) Testis with tunics; (b) Epididymis with tunics; (c) submandibular lymph gland; (d) lepromatous patch from scalded skin area.
Clinical photographs $a, b, c$, of the testis and the epididymis in situ were taken.
Report of histopathological studies by Dr. Sundarasiva Rao, m.D., Professor of Pathology, Government Ramnarayan Ruia Medical College, Tirupathi:-
Testis-Marcoscopic size $2^{\prime \prime} \times 1 \frac{1}{4}{ }^{\prime \prime} \times 1 \frac{1_{4}^{\prime \prime}}{4}$. Surfacesmooth and glistening. Colour-bluish white. Con-sistency-soft and vascular with no nodules feltepididymis enlarged and hard, particularly globus minor. A few delicate adhesions present between body of epididymis and testis proper.
Testis with tunics: Marked thickening of tunics with atrophy and wide separation of tubules. Hyalinized connective tissue with diffuse round cell infiltration and foam cell collections in the perivascular areas present between the tubules. The predominant change is a granulomatous infiltration of the interstitium with fibrosis and atrophy of seminiferous tubules. 'There is no actual increase in the interstitial cells.
A.F.B. were seen both intra- and extracellularly, in the interstitial tissue as well as inside the tubules. Vangieson showed moderate increase of connective tissue in tunica albugenia and peritubular areas with dilated blood vessels.

a
G.L. S.C. 280/64.

Left testis and epididymis with tunica vaginalis in situ -both enlarged-surface smooth and glistening with a few blood vessels seen running transversely over testis.

b
Parietal layer of tunica vaginalis incised and testis and epididymis exposed. Globus major and body moderately enlarged. Globus minor markedly enlarged and glistening. Delicate adhesions present between the testis and epididymis.


Another view of both these structures, showing relative enlargement and vascularity.

Epididymis with coverings: Showed comnective tissue with dense diffuse chronic granulomatous infiltration around the vessels and obliterating them. The tubules look normal with moderate thickening of intertubular connective tissue. A.F.B. mostly extracellular were seen in the tunics only, sparing the epididymis proper. No actual chronic inflammatory cell infiltration and presence of A.F.B. could be made out in the epididymis proper. It looks as though the tunics only are involved sparing the epididymis. Submandibular lymph gland: Sections showed necrosis, epithelioid and giant cell reaction, with follicle formation. Few sections examined did not reveal A.F.B. organisms. However, considering the large number of foam cells, the lesion is only probably lepromatous.
Lepromatous patch from scalded skin area: There is atrophy of skin with flattening of papillary layer. Diffuse inflammatory round cell infiltration in perivascular, periglandular and perineural layers present with granulomatous changes.
All sections were examined after H \& E, Vangieson and Acid Fast staining.

## DISCUSSION

X \#! ( ( $\mathfrak{n}$ र \# \#" \$








 ( \# \# \$ +


 4Q\$) ("@ -

 "5ก̃x



 \$*
Ă) $\mathrm{D} \$ 4 \hat{1} \mathrm{D}^{1}$ *
 - "D= గั้ ! !\#@!




 * \# $\$ \mathrm{a}$ * - 邓Û̂̃ D *


 $a^{\prime} K() *$ ñ \& กñN) *c







summary


 \#Ò Ẹ́̆

## ACKNOWLEDGEMENTS


 " 7 p Q Q ø\#

 м.D., a' E




 ùDu a) * ก़̃ "ñ \&













## references

1. cunningham, d. J. (1962). Testis and Epididymis -Cunningham's Manual of Practical Anatomy, pp. 172-179.
2. davey, t. f. et al. (1964). Endocrines in Leprosy. Leprosy in Theory and Practice, XI, pp. 190-192.
3. furniss, a. L. (1956). Testis in Leprosy. Ind. J. Med. Sci., X, 7, 506-509.
4. Јов, с. к. et al. (1963). Leprous Orchitis in Reactional Borderline Patients. Int. .J. Lepr., 31, 273.
5. khanolkar, v. r. (1964). Pathology in Leprosy. Leprosy in Theory and Practice, 8, pp. 131-132.
6. коbayashi, w. (1924). Detection of Lepra Bacillus in Testicular Tissues. Arch. Dermat., 2 (1964), Summary in Jap. Med. World, 4, 269-270 (1924).
7. long, e. r. (1925). Assay on the basis of Spermatocyte Reaction. J. Infect. Dis., 37, 368-384.
8. mitsuda, k. et al. (1937). Study of 150 Autopsies on Leprosy Patients. Int. J. Lepr., 5, 53-60.
9. muir, e. (1962). Lepra Reaction and the G.A.S. Lep. Rev., 33, 240.
10. Ridley, D. S. (1960). A Bacteriological Study of Erythema Nodosum Leprosum. Int. J. Lepr., 28, 254.
11. Robinson, r. h. o. b. (1950). Epididymis. British Surgical Practice, 183-186.
12. Samson and wright (1965). The testis, seminal tract and related glands. Applied Physiology 508.
13. Wade, h. w. (1963). Lesions of testis. Editorial, Int. J. Lepr., 31, 3, 363.

# 1HIGA＇M GRL［0 HIG W［MIO\＆MOUFM 9［ ［－OM X＞［＇R ？H9\＆A OMGGVYHW；\＆Z；D 0 ［ 



－：\＆\＄
 $: ち$ ñō D＂）\＃ — $\mathfrak{I N}$

 n D ก̂̃D＜＊



 7 ：\＄ش⿵冂⿱一廾彡y \＆Cñi\＆＊



 5TKగ్̃ર1 n ĥñ \＄＊




 s qñi\＃\＃（
\＄＊


 s qĩ扰＂y＊
 ç K：＂\＄థ̃ر＂）Dî̃＂ 5 ก̃̃ \＆ 6 ก̃ \＆ 3 ก̃̃－\＄

 \｛ ${ }^{3}$ ก̃K＂


 \＃＂y＊







 \＆\＃，K＂
 ＠1D＇${ }^{1}$＊ \＃\＆n＊


Gた




 y 甶ᄀ＊）K＊ 6 ，＂\＄\＆\＃ñ ：＠థ̣̃
 ：\＄）＊กั์ \＆Dîn h：＊







 DF）＊
conclusions
り＂







## REFERENCES

1. Parikh, a. c., et al. Therapeutics Lederkyn in the Treatment of Leprosy. Indian J. Derm. Vener., 30, 211-213 (Sept.-Oct.) 1964.
2. RAO, s. B. Lederkyn in the Treatment of Leprosy. .J. Mysore Med. Ass., 29, 1-6 (Oct.-Dec.) 1964.
3. RaO, s. B. Treatment of Leprosy. J. Mysore Med. Ass., 28, 1-6 (July-Sept.) 1963.
4. Eisman, p. c. Experimental Chemotherapy of Leprosy. In: Schnitizer, R. J. and Hawking, F. ed. Experimental Chemotherapy, Vol. II, New York, Academic Press, 1964, 501-558.
5. Ghosh, s and chakaborty, b. k. A Long Acting Sulphonamide in Treatment of Leprosy: Preliminary Report. Bull. Calcutta S'ch. Trop. Med., 12, 33 (Jan.) 1964.
6. YAWALKAR, S. J. and AURANGABADKAR, J. w. Newer Drugs in Leprosy. Indian Pract., 18, 75-78 (Jan.) 1964.
7. Merklen, f. p., et al. Regression of a Mycetoma of the Foot in a Leprous African after Large Doses of Sulphamethoxypyridazine. Sem. Hop., 41, 425 (Feb. 8) 1965.
8. basset, a. and basset m. Trials of New Drugs in the Treatment of Lepra. Bull. Soc. Med. Afr. Noire Lang. Franc., 9, 418-4ン1, 1964.
9. Ghosh, s. General Principles of Treatment of Leprosy. Bull. Calcutta S'ch. Trop. Mer., 13, 27-30 (Jan.) 1965.
10. Languillon, J. The Leprous Reaction, Definition, Clinics, Pathogeny, Therapy. Med. Trop., 25, 171-18: (Mar.-Apr.) 1965.
11. asshauer, $E$. Lederkyn in the Treatment of Lepra. Z. Tropenmed. Parasit., 16, 73-76 (Apr.) 1965.
12. Chang, Y. т. Effects of Capreomycin, Ethambutol, and Five Long-acting Sulphonamides in Murine Leprosy. Nat'l. Inst. of Arthritis and Metabolic Diseases, Bethesda, Md. Abstract of papers sustained at the 4th Inter-science Conference on Antimicrobial Agents and Chemotherapy. Oct. 26-28, 1964, N.Y., N.Y.
13. cochrane, R. G. Chemotherapy of Leprosy. Practitioner, 188, 1123 (.Jan.) 1962.

# 10 TOEMKT0［09 \＆）＜？ $\mathbb{A} \& \triangleleft \mathbb{G} E[E[0 \quad$ HIG $\mathbb{W}[$ 

#  <br> Āா 


ロ


Causes of Dehabilitation








 \＆\＃ौं＠\＆＂＊
 ）\＄＊DiD＇）\＄＊
 \＆＂1 กั＂＊ ＂／ก̃\＆
 ＂ 5 री \＄o \＃\＆\＃กn $\$ *$ 管！！ \＆ก̂̃，）K\＆D＊＊

 ＂$\$$（而（ 1 ＊
 DK＂1 \＄：\＃＊
 \＆










 DK\＆
 ！

 DL ！！前 $\$$＊

 ̂ \＃ñ TD \＃＊







 ．


 กШジß

X\＆D Ù！ $\mathrm{\#}$ Й \＆




## 

皿



 ＇＂s A＂ 0 ＊












 ！品
 G\＆$\alpha$ 号 La＊










 Dz册（






 1 Q


 Ćñ1（\＄A ${ }^{\prime} 7$＊










 R A＂\＃\＃ñ̃e，（lñ \＄＊





## 


 5）\＄＇！＂



 ＊＊！！$\$$ ！＞ñ \＃＇＂\＄＊A




## й

 सC\＄Al－）ก̃̃＂



 － 44 A






 U ૫ \% 4 4 T\%



## 





 ! $19 v$ ! $9 \$$ Tp


 A 89 篍 U





$i!$ Mñil Æ

















 * 590 (@ * Pự̛̂ ทั่


 G \% 5 @! $\operatorname{cin} \backslash=$ =






 I é' Gัa G

 @n̂' \&
 ) \$' $9 \$ \mathrm{U}$ (G) ' 'IG




 - !'4ñ \& \%




 @ @- oṇữf henin @!'GY

## PART g'g

MEDICAL AND SURGICAL ASPECTS OF
PREVENTIVE REHABILITATION


 i \& \& प̛̉
 Y゙5
$7 v$ \$\$! 4

 $-v=\hat{\sim}$


］］Z



 ）\＄＠ŕ］9G 8












 ［＇）\％G
¢\＄
 －＠！］！Fñ̃ว Z




medical management











 \＄åN゙NH





 1906 ，ખ）đ̈\＄4
 Z\％4［ñ̃！ 1 ĉ

 ！\＄［苁！\＆ ［＠！Z ］ $7 \%[G \tilde{T} E \mathrm{Q}$ Q


 E \＆\％出＇！ $9 \$$ సָ

 ＇ $9 \$ 9$ \％






G



 \＆！海 \％\％กั95
 5）\＄＇Q \＄

3／4 \％





3／3 \％ 1 B！గñ！＠＠9－！］！！！$\$$ กñ \＄Z

 ＇ $9 \$ \%$ ］



 IJ99E 筸\％［）］Zก̣̃a\＄
 ）\＄＠7］9G＠\＄ก̃ 5\％＠ĩ $66 \%$ 9 1017 ！\＄［ก̂̃＇）\％Z ̂̃95 $90 \%$ 95ñ̃ \＆F గ̣̃7 ！\＄［ñ \％）Z
 ş) - - 筸"" ? ठ \% \%
 * /"\%!! स्त̃ ! !






 Ê\%) , ก̃̃ \$* ) À \% !" \$ñ \$*




 ถ้ $\mathrm{R} \$$ \#ก̂̃"
ă ! \&



 \$ *
 \$*

 * C \% ก̃̃) \$ ! (ñ\# ' \&



 ! "


 - '", กิ̃


 \$*
 \$*
 \# ş!") \#


 \# \% ก̃ "/ñ - \# \$ !\#diñ ? \&í \&ñ ! ! ) $\$!3$ Š\# (Àựi\$




## surgical management











qíñ! ! \#iñ Wh'! \$ ก̃ "ก̃ **
 \& กั̃ \#, ก̃̃ !, กั̃ \&



 \# \% ! ! ( ' \& \& à (ñ b' ( ${ }^{\prime}$ '




 ş ć*)' !" \$ñZ \%"*











 B ! 0 *











 ／＂p解広所 4 ＂



 ＇é口，＂\＄



## SUMMARY






 A＇！！！！！＋＋







 éッグ



## ACKNOWLEDGEMENTS


 $\$^{*}$ ก̃ $\&+\hat{T}$

 $!$ ！＿l coñ
 \＃！＋！！＂）\＃ñ \＄\＄



## BIBLIOGRAPHY

brand，p．w．The Place of Physical Medicine and Orthopaedic Surgery in Leprosy．Lep．Rev．（1954）， 25，5－10．
brand，p．w．The Value of Surgical and Physio－ therapeutic Measures in Leprosy．Lep．in Intia （1955），27，131－137．
brand，p．w．Treatment of Leprosy．The Role of Surgery．New England ．J．Med．（1956），254，64－67．
brand，p．w．Treatment and Prevention of Deformities in Leprosy．VII Internat．Cong．Leprology， 1958 ， Tokyo，pp．260－263．
brand，p．w．Life after Leprosy through Rehabilitation． Rehabilitation Literature，Vol．21，No．8，Aug．， 1960.
Doull，J．A．The need for study of the potentials of Surgery and Physiotherapy in Leprosy．Int．．J．Lepr． （1959），27，202－215．
hemerijckx，f．Report on the activities of the Belgian Leprosy Centre，Polambakkam（1955－1958）．
hemerijckx，f．The Pattern of Social Assistance in Countries of High Endemicity．VII Internat．Cong． Leprology，1958，Tokyo，442－447．
jagadisan，t．n．Rehabilitation of the Physically Handicapped with reference to Leprosy．Lep．in India（1948），20，142－145．
karat，mrs．sakunthala．Management of Anaesthesia and Paralysis of the Limbs in Leprosy．J．Christian Med．Assoc．India，Feb．， 1966.
karat，mrs．sakunthala．Problems and Care of the Foot in Leprosy．J．Christian Med．Assoc．India， March， 1966.
karat，a．b．a．Clinical Manifestations and Medical Management of Leprosy．C．M．C．Vellore，Alumni J． （Oct．，1966），1， 2.
kessler，h．h．The Principles and Practices of Rehabilitation．Philadelphia，Lea \＆Febiger， 1950.
manuel，c．Rehabilitation in Leprosy．Lep．in India （1958），30， 65.
price，e．w．Studies on Plantar Ulcers in Leprosy． Lep．Rev．（1959），30，98－105．
price，e．w．Studies on Plantar Ulcers in Leprosy， IV．Etiology of Plantar Ulcers．Lep．Rev．（1959）． 30，242－248．
price，E．w．Studies on Plantar Ulcers in Leprosy． V．The Complications of Plantar Ulcers．Lep．Ret． （1960）， 31 97－108．
rusk，h．A．Rehabilitation Medicine．St．Loins， C．V．Mosby Co．， 1958.
teichman，g．o．Prevention of Deformities in Laprosy． Lep．in India（1949），21，135－139．
world healty organtzation．Scientific Meeting on Rehabilitation in Leprosy．Wld．Health Org．Tecl．n． Rep．Ser．，1961， 221.

## 44 Leprosy Revieu

# A＂SITOW［F4［M90［0LR＠MLF5［0L：／0E，0［ E［ \＆E［ VH OJ：A OEO\＆？D 9\＆）：＠M\＆：ME［\％E：MG I［ O HIFLW［ <br> \＆M：OE M［ 

 $\mathrm{N} \square$ \＃<br> <br>Mrs．el eas ñã Öeと $\Delta$ ก̂   ［प\＃ 









 Ët \％\＃！\＄ñ̃＊！（第＂（0 ù ñ \＄＊





 \＆L＂\％

 g！b \＄ñ．\％解 3 ＂
 ．＂）\＄－ไin \＄







A SURVEY of the results


 \＄＊


 \％\＄＊\％＊





 q等！！



 3！L悀＂

 ？\＆＇\＆


[^2]




 ! ! : Ç ; C Cis C5









 ! $\ddagger$ \# \& $£$ * 0 角! ; x RǒQ̃0 81



 $A 孔$ е்
 0 ' $̂!A_{1}$ ก̃



 !








1. ठ $ٓ \bar{\omega} \dagger ; 0$.





 !f; ! 8 8

 $\sim A C 3!8$ * గ̂? Ç\&








o ) Y!S






 - \#


DISCUSSION OF FINDINGS
 $50(0 c$ ? $)$ -
 'CS8) ' ; * $\mathfrak{T} ?$



Table 1

|  |  | Total | Follow-up |
| :--- | :---: | :---: | :---: |
| No. of persons interviewed | $\ldots$ | 30 | 30 |
| No. of persons circularised | $\ldots$ | 45 |  |
| No. of replies received | $\ldots$ |  | 26 |
| Total numbers contacted | $\ldots$ | 75 | 56 |

Percentage of follow-up: 74.6\%




 $5^{\prime} ; \mathrm{CA}$ กิּ



$f \ll$ a đ̃ ¢ ð Ä\＆
 feancombl बik＜






 ${ }^{c} A^{\prime \prime} 1$ ทั゙
 ＇＇$\infty$＊
 \＃＇！＇f $\operatorname{Cl}$ ก̃ ：Ä＜\＄＊＊ iXf－0 0 ก̃̃ï－wîn

Table 2a


Table 2b

 b1 Al \＄K＊
 \＆＿®\＆


Table 3

| Carpentry ．．．Making | 18 |
| :--- | ---: |
| Toy Mardening | 26 |
| Kitchen Gard | 2 |
| Poultry Keeping | 2 |
| Miscellaneous | 8 |

 B \＃Afí\＆f \＃ñ ！乙1î＂．W S －ก̃̃\＃：＊
 ＇fAI \＄A 管A






万\＆！ATff \＄f \＃\＆\＆Etin b＜B，！$<$ \＃ ช！！

 ＜ ト＿\＃＊ －．$\tilde{n}^{\prime \prime}$ ！

Table 4



＂\＃ก̃̃＂ $5 \hat{̃}$＂$)$ A
 fA $\tilde{n}^{*}$ gfil \＄ñ̃ ？Añ̃ fím＇ı ？＂เ Ơñ \＃Wก̣̃ \＆AI＂A กñ ！，1＂AÉ\＄ 1＂＇fぐ\＄





 $\mathrm{E} \gg$ 局






Table 5
Marital Status of Ex－Members
Single

[^3]
 （！$!\$ 4$ 荅＂$\%$ ノ（




















 \＆－！－（J）！＂\＄
 $\$$ 侖
conclusions


 1 P缺 \＄







曰 $\% \times \infty$ \％

 ub $\rightarrow$ กñ＂
 ） 1 ＂$\$$ रू？\＆\＆\＆
 ＂／









 i＂＇」！＂\＄踊


 ！$\$$ 亿̃ $\$$ ．
 $\$$＂










兀＂）«n̂̃a＇ \＆＋Tinc＂ $!L * E=\%$ ñ L＊
 \＆i＋＋ĩL＂ ，）\＃ก̃̃－＋



 7＂－Ï（． \＃＇\＆ E \＆！\＆



 ＇＂，，）L！！＋
 XŬ＋，ก̃ ）\＃



 －\＃＇ñ̃\＃＇！＋．ก̃ं L
 \＆＋









 L＊


 \＆ $\mathfrak{n}$ \＆！垌 L






 ＊）\＃＇！+ \＃̃ ${ }^{\prime}$ L
 ）4\＆ก̂̃＂




 b L \％\％




 \％＇\＃＂L\＃－！（Ĥ．గ̃ L＊
 ЯP\＆$\quad$ 多\＃

## OHGIP［

## Positive Living <br> Leprosy and the Spirit of Man

－GĩX © ¢



 \＃TNN＂T＊





 s）Niño：\＃ ç＂）\＃8 ̣̂̃ ก̣̃ g g ก̣̃＊3＂N＂T も＂）TNTI
 OA กุ̃＂／ก̃̃N















 ＊ 1 N \＃ñin＇
 $N$ øñg：\＃

[^4]
##  

SCIENTIFIC ADVENTURE AND COMPASSIONATE ACTION
＂\＃ñ ：／ F ：TNm $n$ ก̃ Z3 TN \％
 ＇＂3 g 8
 ＠CT4

 ē N－广 ÄNT̃E \＃
 Nุ̂̃＂，－ 2 กñ E \＆＇\＆$\tilde{n}^{2}$ Z


 \＃N゙リ分等 \＆：T8







FALSE ASSUMPTIONS
X\＆ก̣̃ dē＇＊


 8\％＊






 0 OTO Od \＃



 W笑く＂＿í\＆ －（ 3 กñ＂＂





CONSTRUCTIVE ACCEPTANCE OF THE ILLNESS

 प\＆

 ロ
 ாСா
 ジ
 प \＆К К
 ロ ＇

 ロ
 แ ตா


 （

WORLD PROBLEM
 1\＆\＃＂＜B 1．ก̂̃ W＊ E\＆ －Wuñ＊d W＊š＊







 I WB＜＊


 W












 әі価
 3 ก̂＜＜पñ W＊











 al Oと



 －で以






ACKN（）WLED（iEMENT
к ；＋ÔỘ̃o oa



 ；己＋ñ̃e＋＠！\＄B

REFERENCES
1．WHO Chronicle，14，I，January， 1960.
2．Who Walk Alone，p． 70 ．

## 0 M M OIU FM 90［．：M FI［



 b＂ã̌̂ÂÊ



 N̦＂H＂\＃＠
 ð．\＄，：H
 s＂tč＠Й̃M．D．

Uた－గ̂̃ ，a\＄＂

 \＃＠1；＂＠







 O＋1バ＂\＃氐

Roy E．Pfaltzgraff，m．d．



## ש セ ロ В




＾č！


 §！＋\＆（ćo H（\＃\＄




 ；！＂\＄



 ̂＂d＇4 $\mathfrak{n}$ ë +1 H゙\＃B！）＠
 ＂\＄（．ñं＊＋＠＂\＄\＃B；＋



 ；čtinqき + b e；）＊．ก̃̃U＂）B a\＄HI ก̂̃ dH
 1963.



 ＊＊a ！＂\＄ก̃̃；\＆＋



 1）－áa ；！＂\＄
 ) \# กั
 Āx Đ


 ) $^{-}$। $\tilde{n}^{\prime}$ \# \# स z \$. ก̣̃n 9 -Rū 制


 éĐn * \#





REFERENCES
browne, s. g. (1965). A limited clinical trial of injectable Thiambutosine. Lep. Rev., 36, 21-22.
cochrane, r. g. (1952). The action of sulphones in leprosy, with particular reference to histopathology. Trans. Roy. Soc. Trop. Med. Hyg., 46, 122-126.
goodwin, c. s. (1963). Essentials of leprosy for the clinician, 1st Ed., 4. Hong Kong: Hong Kong Auxiliary of The Mission to Lepers.
goodwin, c. S. (1967). The significance of Mycobacterium leprae in the nasal mucosa, with special reference to Chinese leprosy patients. Lep. Rev., 38, 181-188.
pettit, J. h. s. and rees, r. J. w. (1964). Sulphone resistance in leprosy. Lancet, 2, 673-674.
waters, m. F. r. and rees, r. J. w. (1962). Changes in the morphology of Mycobacterium leprae in patients under treatment. Int. J. Lepr., 30, 266-277.

$$
\begin{aligned}
& \text { elýa M Mrowne. }
\end{aligned}
$$

## * L M\& , ML

1. Effect of X-Irradiation and Thymectomy on the Development of Mycobacterium Leprae, Infection in Mice, by J. M. Gaugas. Brit. .J. F.xp. Path., 1967, 48, 4, 417-22.

Using the mouso hind foot pad technique first described by Shepard, inocula in the order of $5.0 \times 10^{3} \mathrm{M}$. leprae bacteria showed a limited type of multiplication. General immuriosuppressive treatment by thymectomy, potential lethal irradiation ( 900 r . in mice then protected by marrow transplantation) or repeated sublethal doses of x-rays (420r.) produced only a slight increase in susceptibility to infection. However, thymectomy combined with 900 r . did provide much higher yields of bacteria. This combination led to a maximum 16,800 -fold increase of the total initial iroculum number of bacteria from its inception in contrast to a 560 -fold increase in untreated controls. The nature of the host's defensive mechanism which then halts multiplication is uncertain. Macroscopic lesions were not found and there was no spread of infection from the site of inoculation.

From the author's summary.

The following 6 abstracts are reprinted, with permission, from Trop. Lis. Bull., 1967, 64, 7:
2. Leprosy survey and control pilot project HMG-Nepal, by I. B. Mali. J. Nepal Med. Ass., 1966, 4, 4, 330-38.
This work has been carried out in Nepal, where little work has been done on leprosy, and Dr. Mali of Kathmandu reports on his activity in a leprosy survey and the setting up of a control pilot project in Nepal sponsored by Emmaus Suisse. A WHO short-term consultant reported a prevalence of leprosy of 10 per 1,000 but Dr. Mali found a prevalence of 5.7 per 1,000 in a village survey and 1.5 per 1,000 in a school survey. (In spite of these diverse figures it is probable, in the abstracter's opinion, that the final figure will be in the neighbourhood of 10 per 1,000 based on experience in other parts of the world wheresurveys have been done.) The number of patients attending for treatment has already increased greatly.

This pilot study is laying a good foundation for a controlled scheme and the success of the project ultimately depends on the interest developed by the national staff.
J. R. Innes.

Acid-fast bacilli in the bone marrow of leprosy patients, by A. B. A. Karat. Int. .J. Lepr., 1966, 34, 4, 415-19.
At the Schieffelin Leprosy Research Sanatorium in South India 413 'consecutive admissions' (apparently not all were untreated patients) were subjected to sternal puncture, 235 of the patients having lepromatous leprosy, 33 borderline, 82 tuberculoid, 10 purely neural and 53 indeterminate leprosy. Classification was based on clinical and histological features. (A more detailed classification such as that of Ridley and

Jopling, this Bulletin, 1962, v. 59, 790, might be expected in such a research sanatorium.) In $47 \%$ of the patients with lepromatous, $15 \%$ of those with borderline and $4 \%$ of those with indeterminate leprosy acid-fast bacilli (AFB) were found in the bone marrow aspirate, but none were found in patients with tuberculoid leprosy. (The density of the bacilli is not mentioned.) There was no apparent relationship between AFB in the marrow and age, or duration of the disease. It is stated that the higher the Bacterial Index (BI) the more frequently were AFB found in the marrow (but the histogram shows that AFB were found in the marrow of $76 \%$ of patients with a BI of between 2.0 and 4.0 , but in $68 \%$ of patients with a BI greater than 4.0; the number of patients in each group is not reported. There is no statistical analysis of the differences between the groups). Of 8 patients with 'dimorphous' leprosy (presumably the borderline patients referred to elsewhere in the paper) who had negative skin smears, I patient had AFB in the bone marrow; of 53 patients with indeterminate leprosy who had negative skin smears, 2 had AFB in the marrow; and of 38 with lepromatous leprosy who had negative skin smears, 4 had AFB in the marrow.

It is suggested that bacilli in the viscera may take much longer to be eliminated than bacilli in the skin, and the presence of bacilli in the reticuloendothelial system in patients with negative skin smears may be the explanation of reactivation of the disease. The morphology of the AFB in the marrow was noted, patients with a high BI having a 'preponderance of intracellular rod forms' in the ma.row. and the significance of this finding in relation to the fact that the temperature of the bone marrow is usually $2-3^{\circ} \mathrm{F}$ above the skin temperature is noted (the percentage of evenly stained bacilli in the marrow and skin is not reported). Exacerbation of leprosy was not accompanied by a rise in the incidence of AFB in the bone marrow. $27 \%$ of the patients with lepromatous leprosy had a megaloblastic bone marrow.
(This interesting study merits more detailed reporting and analysis, which the author intimates will be forthcoming.)

## C. S. (Goodwin.

## Histoid (high-resistance) lepromatous

 leprosy, by E. W. Price and M. Fitzherbert. Int. J. Lepr., 1966, 34, 4, 367-74.In Ethiopia the histoid variety of lepromatous leprosy (Wade, this Bulletin, 1964, v. 61, 673) is not uncommon. Ten patients are described, 3 in detail with photographs and histological reports. The presenting symptom was in each patient facial nodules, resistant to sulphone therapy, with the general condition of the patient being 'good'. Photographs illustrate the usual distribution of the nodules in clusters in the middle of the forehead, on the cheeks, at the tip of the nose and on the chin. The ears were infrequently involved, the eyebrows persisted and the nasal mucosa was less affected than would be
expected from the degree of nasal nodulation. Flattened lesions on the limbs and buttocks are described. The skin adjacent to the nodules was remarkably uninvolved. The characteristic histopathological features of the lesions are listed. The granuloma was composed almost entirely of densely packed macrophages, some with foamy change, and a few lymphocytes were seen. Connective tissue septa occurred in large nodules, the peripheral cells of a nodule lying tangentially, while in pedunculated nodules a capsule of collagen fibres was found. The skin appendages appeared 'resistant' to the granulomatous tissue, although intraneural acid-fast bacilli were seen. The nodules were unaffected by therapy with sulphones, thiambutosine, sulphamethoxypyridazine and ditophal but they responded clinically and bacteriologically to sulphormethoxine (Fanasil, sulphorthomidine). The initial dosage was 125 mgm . weekly rising to 1 to 1.2 gm . weekly after 2 months. Treatment frequently resulted at first in oedema and ulcertaion of one or more nodules. No patients were found to have albuminuria or jaundice. Of 10 patients treated with sulphormethoxine 7 showed notable diminution of the nodules, I showed only slight improvement, I developed severe ulceration, and 1 who developed severe joint paints showed bacteriological but not clinical improvement. A table summarizes the details of each patient. The pronounced collagen reaction in the nodules is compared with the situation in nodular subepidermal fibrosis. It is suggested that this type of leprosy be termed 'highresistance' lepromatous (but the appellation histoid has priority and is less restrictive. This report is a significant contribution to the literature of a littleknown form of leprosy; but fuller details of the condition are desirable, including the morphology of the leprosy bacilli in the nodules, a more detailed bacteriological index, the lepromin reaction and a longer follow-up).
C. S. Gooduin.
5. Calcification of peripheral nerve trunk in leprosy. Report of a patient, by K. Ramanujam and G. Ranu. Lepr. India, 1966, 38, 4, 185-90.
Although nerve abscesses in leprosy are 'frequent' in India, apparently no previous report has been made of nerve calcification in an Indian patient with leprosy. After a review of the literature on nerve calcification in leprosy a description is given of an Indian woman who 20 years ago had an erythematous patch over the dorsum of her right foot which subsided without treatment. The right lateral popliteal nerve in the popliteal fossa, and the musculocutaneous nerve in the lower third of the leg anteriorly were thickened and felt bony hard over a distance of 2 inches, and were not tender. There was no motor deficit in the leg or foot. Skin smears revealed Moycobacterium leprae, and the lepromin reaction was strongly positive. Histological examination of the musculocutaneous nerve revealed a hyaline homogeneous mass with only a few nerve fibres in one small area. No acid-fast bacilli were seen. Four radiographs demonstrate the calcified nerves. The mechanism involved is suggested to be dystrophic calcification in the wake of abscess formation.
C. S. Goodwin.
6. Les thérapeutiques spécifiques actuelles de la lèpre (The specific treatment of leprosy), by J. Languillion. Med. Trop., 1966, 26, Spec. No., 131-56, 24 figs. on 6 pls .
After a brief but useful historical introduction to the modern treatment of leprosy, this long review summarizes existing knowledge concerning the principal drugs now used against the disease (excluding those employed in reactional states).

Pride of place is accorded to dapsone, and the monoand di-substituted sulphone derivatives. The mode of action, dosage and toxicity of members of this series of drugs are reviewed, together with practical advice on methods of administration of the oral and injectable forms of dapsone. The results of treatment are briefly catalogued. The section on thiambutosine provides unexceptionable data arranged along similar lines. The author's interest in the long-acting or depot sulphonamides is reflected in the length and authoritative nature of this section, which gives the best (if somewhat over-enthusiastic) résumé available of the use of this series of drugs. An excellent selection of paired photographs-'before and after'-follows the letterpress.

As a work of reference, this article is of value in providing a reasonably comprehensive survey of the drugs at present available for the treatment of leprosy. It is of less use as a guide to treatment, and provides neither criteria for critical comparison nor indications for choosing one drug rather than another.
(The author's conclusion that lepromatous leprosy is never cured-a conclusion based on the persistence of acid-fast bacilli in the deep organs-will sound unduly pessimistic to many, while his assertion that the sole test for true cure is the 'negativation' (sic) of the Mitsuda reaction is either a misprint (for 'positivation') or an impossible ideal-or both.)

> s. (i. Browne.
7. Dapsone assay based on Schiff base formation, by L. Levy and L. J. Higgins. Int. J. Lepr., 1966, 34, 4, 411-14.
Dapsone is used in the treatment of leprosy and malaria in doses that result in extremely small tissue and blood concentrations and there is need for a more sensitive method of assay. A method is described, based on the phenomenon of Schiff base formation between 4-dimethylamino-benzaldehyde and dapsone, which is more than twice as sensitive as the commonly used Bratton-Marshal method. A comparison of the 2 methods is made with the use of standards and blood from one patient under treatment with dapsone. The method is admittedly relatively complex, and measures 'free' dapsone only. However, conjugated dapsone is present in only minute amounts and is probably biologically inactive.
S. M. P'arrack.

The following 3 abstracts are reprinted, with permission, from Trop. Dis. Bull., 1967, 64, 8:
8. Genetic influence in leprosy, by P. Mohamed Ali. Indian J. Publ. Hlth., 1966, 10, 4, 145-55.
This paper shows from studies conducted from the

Central Leprosy Teaching and Research Institute, Chingleput, S. India, that the incidence of leprosy is in part genetically determined. During the past 4 years a census survey in a heavily infected district of Madras State in a population of 200,000 showed that factors like sanitation, housing conditions, economic status, literacy, nutrition, had no significant influence on the incidence of leprosy; there was no correlation between the patients and the size of the family; and there is no basis for the theories of adult insusceptibility and the necessity of prolonged contact for contracting the disease.

The following facts are cited in support of the genetic theory: l. The significant difference in the sex ratio vis-à-vis lepromatous leprosy particularly. 2. The 2 decisive periods when infection was found to occur. 3. The greater concordance among the monozygotic twins in the incidence of the disease. 4. The tendency of the disease to cling to families. It is concluded that there is a dual aetiology for leprosy-infection with Mycobacterium leprae and an inherited individual susceptibility. Certain suggestions with regard to anti-leprosy campaigns in the light of a genetic basis for the disease are also given.
J. R. Innes.
9. Incubation period of leprosy, by K. V. N. Prasad and P. Mohamed Ali. Indian J. Med. Res., 1967, 55, 1, 29-42.
' 1 . The data collected on the multiple-patient families during the course of a general leprosy survey in the Chingleput District of Madras State are utilized in the estimation of the incubation period of leprosy.
' 2 . The changes in the incubation period are studied in relation to the sex and type of leprosy of the Index patients and age and sex of the secondary patients.
' 3 . The incubation period is the same whether the index patient is male or female.
'4. Although no clear-cut significant results are obtained in all patients, a consistent difference is observed in the incubation periods between the 2 sexes, always being less in females.
' 5 . There is an association between the age and the age at onset of disease in an individual and the incubation period is more in adults when compared to children.
'6. In all the categories considered, the incubation period is longer with lepromatous type index patient when compared to the non-lepromatous index patient.
'7. Though there is no significant difference between the estimates of the incubation periods among the corresponding categories of the secondary patients in 2 types of index patients, we observe a notable difference between the estimates in the 2 types. Since the significance is not clear, it is difficult to explain the observed difference on the basis of the available data.
' 8 . The incubation period is the longest in the case of adults having lepromatous type of leprosy as index patient, its value being 85.3 months.
' 9 . The incubation period is shortest in the case of female children having non-lepromatous type of leprosy as index patient, its value being 29.6 months.'
10. Leprosy prophylaxis, by P. Fasal, E. Fasal and L. Levy. J. Am. Med. Ass., 1967, 199, 12, 905-8.

At the Leprosy Clinic of the U.S.P.H.S. Hospital in San Francisco during the last 7 years 198 family contacts of patients with lepromatous leprosy have been examined, and 16 have developed leprosy, an attack rate of $8.08 \%$. The previous policy of 'watchful waiting' has now been changed to a programme of $B C G$ vaccination of all contacts, except those with 'large' tuberculin reactions or pulmonary lesions found by chest radiography. Repeated tuberculin testing with revaccination of non-converters will not be carried out. The reasons for this new policy are delineated. The relative value of prophylaxis with dapsone or BCG is discussed. The reduction of the risk of infection by $51.2 \%$ with the use of prophylactic dapsone in bacilliferous leprosy contacts (Dharmendra et. al., Lepr. India, 1965, v. 37, 447) is compared with the reduction of the risk of infection by $79.9 \%$ when BCG was given to contacts of all forms of leprosy (this Bulletin, 1966, v. 63, 413). An analysis is also made of 3 other, admittedly incomplete, studies of BCG prophylaxis when the reduction in risk of infection ranged from $88 \%-95.5 \%$. The suppression of multiplication of Mycobacterium leprae in mouse footpads by BCG (this Bulletin, 1965, v. 62, 880) is cited in support of the BCG policy. (No other reports on dapsone prophylaxis are mentioned.)
C.S. Goodwin.

The following 3 abstracts are reprinted, with permission, from Trop. Dis. Bull., 1967, 64, 9:
The etiology of erythema nodosum leprosum, by J. H. S. Pettit and M. F. R. Waters. Int. J. Lepr., 1967, 35, 1, 1-10.
'An appeal is made for recognition of patients of erythema nodosum leprosum and designation as such. A study of 60 patients of ENL has confirmed earlier suggestions that the reaction appears only when the great majority of leprosy bacilli in the patient's tissues are no longer viable. This, in conjunction with other findings, emphasizes the fact that incrimination of the sulfone drugs as the causative agent of the reaction is untenable. Therefore the cessation of sulfone treatment during the course of ENL is not only illogical but is potentially dangerous to the patient's progress in that it allows any residual viable bacilli to propagate and extend a previously controlled infection.'
(There is a full reviewed discussion of the literature, with 45 references.)
12. Erythema nodosum leprosum in borderline leprosy. Report of a patient, by A. B. A. Karat, C. K. Јob and S. Karat. Int. J. Lepr., 1967, 35, 1, 17-24.
The authors describe a patient with borderline leprosy who developed erythema nodosum leprosum (ENL) during a phase of exacerbation of the disease. Previously it was thought that ENL does not occur in this form of leprosy and this is the first report of the association of ENL with borderline leprosy. The paper is well illustrated with photographs and photomicrographs.
J. R. Innes.
13. The treatment of eythema nodosum leprosum with B663. A controlled study, by J. H. S. Pettit. Int. J. Lepr., 1967, 35, 1, 11-16.

The author has tried to establish a method whereby controlled investigations may be used to assess the value of a treatment in erythema nodosum leprosum (ENL). He studied severe cases which needed a high dosage of anti-inflammatory hormones and found evidence that the riminophenazine derivative B663, in a dosage of 100 mgm . daily for 6 days a week over a period of 14 months, had no dramatic effect on the alleviation of ENL, and that the cessation of sulphone therapy does not demonstrably speed the diminution of the reaction. The results are compared with those by Browne (this Bulletin, 1965, v. 62, 421; 1966, v. 63, 1344) in Nigeria who was using 3 times the dosage given by the present author.
J. R. Innes.

The following 4 abstracts are reprinted, with permission, from Trop. Dis. Bull., 1967, 64, 10:
14. Über filamentös-myzeliale Globi des Mycobacterium leprae (Filamentous-mycelial globi in Mycobacterium leprae), by V. Aplas. Zentbl. Bakt. I. Orig., 1967, 202, 4, 497-502.
The author has examined a cutaneous lepromatous lesion in frozen sections stained by his modification of prolonged staining with Giemsa. By this method extracellular globi of filamentous and mycelial forms, resembling actinomyces were demonstrated. These forms were shown to be non-ocid-fast, were chromophobic and did not stain by the usual histological methods. They were demonstrable by prolonged Giemsa stain, by Sudan black, and in unstained sections could be shown as doubly refractive by polarized light.
(This observation was made on a single petient. It would be interesting if it could be confirmed on a series of patients.)
15. Blood groups and leprosy, hy F. M. Salzano J. Med. Genet., 1967, 4, 2, 102-6.

This is an analysis of published work, with some 50 references. The author concludes that there is no indication 'of any differential susceptibility to leprosy or its form among the carriers of different ABO ) and Rh phenotypes. In relation to the $A B O$ system the data are sufficiently numerous to rule out any important contribution of genes in this system to the variance in this attribute. Information concerning other systems is still too scarce and need not be considered here.'
16. Leprosy and ABO blood groups, by G. Singh and D. Олна. J. Med. Genet., 1967, 4, 2, 107-8.
'ABO blood groups were studied in 633 leprosy patients and compared with 2,583 controls. No relation between blood groups and susceptibility to disease was observed. Lepromatous and non-lepromatous groups of patients did not differ significantly as regards pattern of ABO blood groups.'
17. [Histological study of the derma in patients with leprosy during treatment,] by K. P. Popov and Gia-Kulen Nguen. Vest. Derm. Vener., 1967, 41, 5, 27-30. (In Russian.)
The English summary appended to the paper is as follows:-
'The authors examined 205 patients with leprosy, of whom 62 were over 7 years from the onset. Histologic changes in the derma after treatment with DDS, rimiphone, streptomycin, novocaine and penicillin are described. As a result of treatment sclerosis of the derma is formed and leprous infiltrates are resolved, indeterminate leprosy yielding to treatment readily while lepromatous leprosy is more difficult to treat.'

# G G =[! 0 T:OU[ 

The Flowering Wilderness, by Wilfred H. Russell, в.А., 88 page.s, 31 illustrations, published by The Leprosy Mission, 7 Bloomsbury Square, London, W.C.l., price 3.s.
'The Flowering Wilderness', with a foreword by Sir Maurice Hallett, a.c.I.E., k.c.s.i., is a fascinating account of the growth and development of the Faizabad Leprosy Home and Hospital in India, from its formal opening in 1938 to the celebration of its Silver Jubilee. It is recommended for careful reading about good work for leprosy. If Gandhi were alive today he would delight in this work and carefully read it.

## Reprints of articles in this Review

Twenty-five reprints of each article will be supplied free where there is one author and 50 reprints where there are more than one author.

Further copies, if required, should be ordered as soon as possible after acceptance of articles for publication; if ordered at least 4 weeks before publication date they can be supplied at the following rates :

| No. of copies |  | Single leaf 2pp | 4pp | 8pp | 12pp | 16pp |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | £ $\quad \mathrm{d}$. | £ s. d. | £ s. d. | £ s. d. | £ s. d. |
| 50 | ... | 1100 | 250 | 300 | 400 | 500 |
| 100 | $\ldots$ | 250 | 2150 | 400 | 550 | 65 |
| 200 |  | 3100 | 450 | 5100 | 7100 | 90 |
| 500 | $\ldots$ | 550 | 750 | 9150 | 1450 | 175 |

Reprints can also be supplied if the order is received up to 5 months after publication date, at the following rates :


The above rates do not include covers, which can be supplied plain, wire stabbed: 50 at 10 s.

Coloured Reprints are subject to special estimate.
All reprints are plus postage.


[^0]:    $2 \mathrm{z} \square\|\|$ Ř

[^1]:    * Presented before The USPHS Clinical Society and Commissioned Officers' Association Meeting, Atlanta, Ga., May 11, 1967.

[^2]:    ＊Present address：Deputy Superintendent \＆Surgeon， The Leprosy Mission，Vadathorasalur，Tiyagadrug P．O．，S．Arcot District，Madras．

[^3]:    Happily married
    Married and separated
    Widowed

[^4]:    ＊Shri Jagadisan is the Organizing Secretary of Hind Kusht Nivaran Sangh（Indian Leprosy Association）． He has devoted his life to serving the sufferers from leprosy，＇with the zeal of a friend，with the generous energy of a father，and with the exuberant affection of a mother＇．It is fitting indeed that here he writes on＇Leprosy and the Spirit of Man＇．

